OVERVIEW
In 1961, Okazaki and colleagues first described Lewy bodies in the cerebral cortex in patients with dementia (Okazaki et al, 1961) . Lewy bodies are difficult to identify when viewing standard hematoxylin-and eosin-stained cortical regions, perhaps explaining why so few additional reports occurred over the following two decades. With the application of ubiquitin immunohistochemical techniques in the 1980s, Lewy bodies in the cortical and subcortical regions were easier to identify. In the late 1990s, soon after mutations in the a-synuclein gene were found in two kindreds with familial parkinsonism associated with Lewy body disease, a-synuclein immunocytochemistry was developed and applied to autopsied brain tissue, and Lewy bodies and Lewy neurites stained intensely (Spillantini et al, 1998) . Neuropathologists can now identify extranigral Lewy bodies with relative ease (Dickson, 2002; Kosaka, 2000) .
Several terms have been used when describing patients with known or suspected Lewy body pathology. These include Lewy body disease, Lewy body dementia, the Lewy body variant of Alzheimer's disease (AD), diffuse Lewy body disease, cortical Lewy body disease, and senile dementia of the Lewy type. The Consortium on Dementia with Lewy bodies (CDLB) developed consensus criteria for the clinical and neuropathologic diagnoses of what is now termed dementia with Lewy bodies (DLB) (McKeith et al, 1996) . Since the contribution of Alzheimer's pathology to the clinical features in DLB is not clear, the presence of the Alzheimer's pathology does not exclude the diagnosis of DLB. Based primarily on cases in hospital-based and referralbased samples, the frequency of DLB is approximately 15% to 25% of cases with irreversible dementia (McKeith et al, 1996) . Controversy continues as to whether patients with typical features of Parkinson's disease (PD) who subsequently develop dementia (ie, Parkinson's disease with dementia [PDD] ) have the same underlying pathophysiologic process as do patients with dementia, fluctuations, and visual hallucinations who subsequently develop
KEY POINTS:
A parkinsonism (ie, DLB), differing primarily in the time course of when the various features became manifest. In this monograph, we will view DLB and PDD as clinical syndromes and reserve the term Lewy body disease (LBD) for the histopathologic disorder. Terms and definitions pertinent to DLB are described in Box 4-1.
CLINICAL FEATURES
A wide variety of symptoms and signs can occur in DLB (Ballard et al, 1999; Ballard et al, 2001; Boeve et al, 2003c; Boeve et al, 1998; Galasko, 2001; Hishikawa et al, 2003; McKeith et al, 2003) (Table 4 -1). The time course of the appearance of certain features also tends to vary, making counseling patients and families about future symptoms challenging. One useful approach to systematically characterize symptomatology and to decide on management is to view features in each of five categories: cognitive impairment, neuropsychiatric features, motor dysfunction, sleep disorders, and autonomic dysfunction (Case 4-1).
Cognitive Impairment
Memory impairment can vary from slight to very severe (Simard et al, 2000) . Many individuals experience executive dysfunction, with difficulties understanding complex or multistep instructions, solving problems, and reasoning (Simard et al, 2000) . Many others experience what some term verbal blocking, in which one tends to lose one's train of thought in the middle of a sentence or conversation. Apathy and bradyphrenia are common. Many also note problems with vision, but no or only minor abnormalities are found when examined by ophthalmologists. Spatial or geographic disorientation can occur, in which patients get lost while driving, have difficulties navigating in shopping centers or malls or even their own homes. Visuospatial impairment is often easily demonstrated in the office (eg, intersecting pentagons on the Mini-Mental State Examination [Ala et al, 2001] ) and on more detailed neuropsychological tests (Mori et al, 2000) . Misidentification errors involving people can occur and are particularly upsetting when patients fail to recognize their own spouse or children. Some believe their own reflections in mirrors are someone other than themselves, sometimes leading to conversations or arguments with the perceived individual. Some of these cognitive features are thought to result from reduced cholinergic activity, while others are likely due to dopaminergic dysfunction.
Fluctuations are considered a defining feature of DLB (McKeith et al, 1996; McKeith et al, 1999) ; this phenomenon refers to periods of time when cognition and arousal are near normal that are in contrast to other periods of more marked confusion or hypersomnolence. Although fluctuations have been difficult to operationalize and measure, tools now exist that differentiate fluctuations associated with DLB from those with other disorders (Walker et al, 2000a; Walker et al, 2000b) . However, the methods for measuring fluctuations have not made their way into routine clinical practice. Whether fluctuations represent neurochemical alterations, one or more sleep disorders, or some combination of these remains to be elucidated.
Neuropsychiatric Features
Another defining feature of DLB is the presence of visual hallucinations (McKeith et al, 1996; McKeith et al, 1999) . These hallucinations are often vivid and well-formed false perceptions of insects, animals, or people (Aarsland et al, 2001 that the visual experiences are, in fact, hallucinations and not actually present and manage to carry out their daily activities relatively undisrupted. Visual illusions, in which objects are perceived as something different than they actually are, can also occur. Some typical examples include perceiving chairs, lamps, or mailboxes as people or animals. Delusions are also frequent and typically have a paranoid quality (eg, beliefs that one's belongings have been stolen or that other people are invading or living in the home) (Aarsland et al, 2001) . One particular delusion can evolve around misidentification errors, in which one believes that his or her spouse has been replaced by an identical-appearing imposter (Capgras syndrome) (Marantz and Verghese, 2002) . Depression is very common in DLB (Aarsland et al, 2001; McKeith et al, 1996) . Anxiety is also common. Auditory, tactile, or olfactory hallucinations are uncommon. Agitation or aggressive behavior tends to occur late in the illness if at all.
The underlying causes for these various features are not fully understood, but dopamine dysfunction is likely involved in hallucinations, delusions, He stated that he had developed dressing apraxia. His symptoms began insidiously, and although they were progressive over time, his wife noted that his functional abilities fluctuated, and some hours or days were far better than others. His past medical history was notable for alcohol abuse in the distant past and long-standing depression for which medical therapy was moderately effective. His sister and maternal uncle developed dementia in their late sixties. Pertinent positives on his review of symptoms were impotence for the past 10 years and, more recently, lightheadedness and near-syncopal episodes upon standing.
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Initial neurologic examination at age 73 revealed a score of 25 out of 30 on the Mini-Mental State Examination (Folstein et al, 1975) , with particularly poor performance on the intersecting pentagons. There was no evidence of apraxia or aphasia. Blood pressure was 170/102 mm Hg while sitting and 118/82 mm Hg while standing. There was limitation of upgaze on extraocular movement testing, subtle hypomimia, mildly decreased alternating motion rates of the fingers and hands, and a mild symmetric postural tremor. The remainder of his examination was within normal limits.
All laboratory studies for treatable causes of cognitive impairment were negative or normal.
Electroencephalography showed moderately severe dysrhythmia and delta slowing. Neuropsychometric testing showed impairment in verbal fluency, cognitive flexibility, and visuospatial functioning, yet preserved general intelligence, confrontation naming, and memory.
Representative coronal magnetic resonance (MR) images are shown in Figure 4 -1. On further questioning, his wife noted that beginning 9 years ago, he exhibited nocturnal behaviors in which he yelled, cursed, vigorously shook limbs, etc, as if he were ''acting out his dreams.'' When awakened, he often described being chased or attacked by people or animals.
Polysomnography showed increased electromyographic tone and two brief episodes of vigorous shaking movements in one hand during rapid eye movement (REM) sleep, thus demonstrating the typical electrophysiologic and behavioral manifestations of REM sleep behavior disorder (RBD). No epileptiform activity was present. He also had evidence of moderate obstructive sleep apnea, for which nasal continuous positive airway pressure (CPAP) therapy was prescribed. His RBD was considered mild enough that pharmacotherapy was not deemed necessary. Nasal CPAP resulted in significant improvement in his alertness, concentration, mood, and psychomotor speed.
Donepezil was prescribed with further improvement in his verbal blocking, apathy, concentration, and mood. Carbidopa/levodopa was subsequently added, and his parkinsonian symptoms and signs improved.
Months later he traveled with his wife for a vacation in the tropics. For unclear reasons, he developed visual hallucinations and delusions shortly after checking into the hotel.
He was brought to the local hospital emergency department, and although the family pleaded with the medical staff not to administer haloperidol to manage his continued on page 86 escalating psychosis and agitation, 2 mg were given intramuscularly, and he was admitted. Shortly thereafter he developed marked encephalopathy, hypersomnolence, and generalized rigidity. He was transferred to another institution, and with gradual titration of quetiapine, his cognition and psychosis improved over a period of weeks, although moderate rigidity persisted.
Over the subsequent 2 years, his cognitive, neuropsychiatric, and motor difficulties changed minimally. At one point he stated, ''I clearly meet criteria for dementia, but my psychosis and depression have remained in check. My orthostatism is my most troubling issue now.'' Representative coronal MR images, performed 2 years after the initial scan, are shown in Figure 4 -1.
Comment. This case illustrates several key concepts in DLB phenomenology, including: (1) many of the clinical, neuropsychological, electrophysiologic, and radiologic features are qualitatively different from those associated with typical AD; (2) the clinical features of DLB are often preceded by RBD by years or decades; (3) other features such as depression and autonomic dysfunction may precede the development of cognitive impairment and parkinsonism; (4) conventional neuroleptics should be avoided in patients with DLB; (5) insight is often relatively preserved in DLB patients; and (6) some DLB patients can enjoy a reasonable quality of life for many years with a comprehensive approach toward management.
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FIGURE 4-1 Coronal T1-weighted magnetic resonance images of Case 4-1 at ages 73 (top row) and 75 (bottom row). Note the minimal cerebral cortical and hippocampal atrophy and lack of significant progressive atrophy on these images. Although there is mild ventricular enlargement, there is no evidence of transependymal flow on T2-weighted images (not shown) to suggest normal pressure hydrocephalus.
and agitation, and serotonin dysfunction is likely involved in depression and anxiety. REM sleep/wakefulness dysregulation has also been proposed as a mechanism underlying visual hallucinations, based on polysomnographic monitoring in patients with PD and psychosis, in which the dream imagery of REM sleep may invade into wakefulness (Arnulf et al, 2000) . A similar mechanism has been proposed to underlie hallucinations associated with DLB (Boeve et al, 2003a; Boeve et al, 2001b) . If further studies substantiate this mechanism, treatments already known to be efficacious in the management of narcolepsy may prove useful in the management of hallucinations, hypersomnolence, etc associated with DLB (Boeve et al, 2003a; Boeve et al, 2001a) .
Motor Dysfunction
Spontaneous parkinsonism (ie, unrelated to dopamine antagonist exposure) is also a defining characteristic of DLB (McKeith et al, 1996; McKeith et al, 1999) . Signs and symptoms include masked facies, stooped posture, shuffling gait, bradykinesia, difficulty with fine motor skills (such as tying shoes and buttoning), sialorrhea, and tremor (Del Ser et al, 2000) . While some patients have a unilateral or asymmetric rest tremor with a ''pillrolling'' quality that is typical of PD, many have a mild-to-moderate postural tremor that is often symmetric. Myoclonus occurs in some patients, which can complicate differentiation from Creutzfeldt-Jakob disease if progression occurs over a short period of time. Many of these symptoms and signs result from reduced dopaminergic activity.
Sleep Disorders
RBD is common in DLB (as well as in PD and multiple system atrophy) (Boeve et al, 2003a; Boeve et al, 2001b; Boeve et al, 2003c; Boeve et al, 1998; Ferman et al, 2002; Ferman et al, 1999) . Affected patients seem to act out their dreams by yelling, screaming, punching, kicking, swinging, jumping out of bed, etc (Boeve et al, 2003a; Olson et al, 2000; Schenck and Mahowald, 2002) (Table 4 -2). The dreams often have a chasing or attacking theme, with the patient attempting to protect himself or herself. When the patient is awakened, the description of the dream tends to match the behaviors that were exhibited. Injuries to patients and their bed partners can occur. RBD often begins years or even decades before any cognitive or motor symptoms develop, and therefore RBD may be the first sign of an evolving neurodegenerative disorder in some individuals. Many DLB patients also have excessive daytime somnolence, in which they struggle to stay awake through the day (Boeve et al, 2001a) . Other sleep disorders in DLB include insomnia, obstructive sleep apnea (OSA), central sleep apnea, restless legs syndrome, and periodic limb movement in sleep (Boeve et al, 2001a) . All of these sleep disorders are important to recognize as treatments exist for each one.
RBD is intriguing as it tends to occur in certain disorders (eg, DLB, PD, and multiple system atrophy) but not in others (eg, AD, Pick's disease, frontotemporal dementia, corticobasal degeneration) (Boeve et al, 2003a; Boeve et al, 2001b; Boeve et al, 2003c) . Dysfunction in brain stem neuronal networks are believed to underlie RBD (Boeve et al, 2003a; Boeve et al, 2003c) . et al, 1999), although the frequency of each feature in DLB has not been systematically studied. Lewy bodies have been found in the intermediolateral column of the spinal cord, reflecting the rather widespread nature of Lewy body pathology in the central nervous system (Hishikawa et al, 2003; Pakiam et al, 1999) .
Autonomic Dysfunction

DIAGNOSTIC CRITERIA
The criteria for the clinical diagnosis of DLB as per the CDLB (or McKeith) criteria, originally published in 1996 (McKeith et al, 1996) , were refined in 1999 (McKeith et al, 1999) ; the clinical and pathologic criteria are shown in Tables 4-3 and 4-4, respectively. A similar set of clinical criteria, proposed by the Consortium to Establish a Registry in Alzheimer's Disease (Mirra, 1994) , is shown in Table 4 -5. Recent clinicopathologic analyses have shown that the accuracy of the clinical criteria has varied widely among groups of investigators (Hohl et al, 2000; Lopez et al, 2000; McKeith et al, 2000b; Mega et al, 1996; Verghese et al, 1999) . Although the specificity for the CDLB criteria is rather high in most studies, sensitivity is relatively low, and further refinement in the criteria is necessary.
One criticism of the CDLB criteria is the lack of details regarding the minimum number and specific extrapyramidal features that should warrant the label of parkinsonism. Also, according to the CDLB criteria, the diagnosis of DLB cannot be applied to those who develop dementia greater than 1 year after the onset of parkinsonism. In other words, the diagnosis of DLB is appropriate for those who have visual hallucinations and/or fluctuations and develop parkinsonism (1) at any point after the onset of dementia, or (2) no more than 1 year before the onset of dementia; the term PDD is appropriate for those who develop dementia more than 1 year after the onset of parkinsonsim. Another criticism is the lack of operational criteria for the determination of whether ''fluctuations'' are present. Some investigators have suggested that RBD should be added as a core criterion for the diagnosis of DLB 
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" (Boeve et al, 2003c; Knopman et al, 2003) . The timing of the onset of visual hallucinations may also be important, as patients with DLB tend to experience visual hallucinations early in the disease course, whereas patients with AD tend to experience them late in the disease course. These and other issues will surely be debated at future consensus conferences. 
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Cerebrospinal Fluid Analysis
No specific findings on cerebrospinal fluid (CSF) analysis that are diagnostic of DLB have been identified as yet.
Neuropsychological Testing
Neuropsychological testing typically shows impairment on measures of attention/concentration and visuospatial functioning in DLB (Mori et al, 2000; Salmon et al, 1996; Simard et al, 2000) . A similar pattern of deficits on neuropsychological testing occurs in patients with dementia plus RBD, in which impaired visual-perceptual organizational skills, constructional praxis, and verbal fluency have been demonstrated (Boeve et al, 1998) . A subsequent analysis in which the neuropsychometric profile of patients with dementia plus RBD was compared with cases of autopsy-proven AD revealed a striking double dissociation, in which the dementia plus RBD group had worse impairment on measures of attention, visual-perceptual organization, and letter fluency, while the AD group had significantly worse performance on confrontation naming and verbal memory (Ferman et al, 1999 ). The findings indicated that patients with RBD and degenerative dementia have a significantly different pattern of cognitive performance from AD, and the pattern of cognitive differences from AD is similar to that reported between DLB and AD (Ferman et al, 1999) . The neuropsychometric features in patients with dementia and RBD who did not have parkinsonism or visual hallucinations were recently reported (Ferman et al, 2002) . Neurocognitive data from groups of patients with a similar dementia severity were compared in those with clinically probable DLB, dementia and RBD without visual hallucinations or parkinsonism, and autopsy-proven AD. neuropsychologically indistinguishable from that of probable DLB, and the features of both of these groups differ from AD (Ferman et al, 2002) . Therefore, in the absence of visual hallucinations or parkinsonism, the presentation of dementia and RBD may indicate underlying Lewy body disease. This study suggests that early detection of evolving DLB may be possible and emphasizes the utility of probing for RBD in the clinical interview and of neuropsychological testing. A recent report on the neuropathologic findings in patients with RBD plus dementia, in which all patients had limbic or neocortical Lewy body disease, emphasizes the RBD/Lewy body disease association and the very low (if not absent) frequency of RBD associated with pure AD (Boeve et al, 2003c) .
Electroencephalography
Studies involving electroencephalography have shown more background slowing in patients with DLB compared with those with AD (Briel et al, 1999) . Although background slowing is not specific for DLB, normal findings on electroencephalography may argue against underlying DLB.
Structural Neuroimaging
In the setting of dementia, structural neuroimaging with computed tomography (CT) or magnetic resonance imaging (MRI) has classically been used to rule out a tumor, abscess, hydrocephalus, etc. The presence and topography of atrophy may, however, provide diagnostic information. There is ample data on the significance of hippocampal atrophy in patients with mild cognitive impairment (MCI) and AD (Jack et al, 2000; Jack et al, 1999) , which stands to reason as the brunt of pathology in AD is in the mesial temporal lobes. Less hippocampal atrophy is evident on CT and MRI scans in DLB when compared with AD and vascular dementia (Barber et al, 2000; Barber et al, 1999) .
Functional Neuroimaging
Parietal and, particularly, occipital hypoperfusion of single-photon emission computed tomography (SPECT) and hypometabolism on positron emission tomography have been associated with DLB (Lobotesis et al, 2001; Minoshima et al, 2001; Turner et al, 1997) . In two studies comparing the occipital hypoperfusion/hypometabolism of DLB with findings in AD, the sensitivity was modest to high (64% to 90%) while the specificity was high (80% to 86%) (Lobotesis et al, 2001; Minoshima et al, 2001) . Additional radiologic-pathologic correlations are necessary to clarify the role of functional neuroimaging in dementia assessment.
Polysomnography
Although RBD appears to be quite frequent in and relatively specific for DLB in the setting of dementia, the positive and negative predictive values of RBD for DLB compared to the non-DLB dementing disorders have not been systematically studied in a prospective unbiased manner. The critical polysomnography (PSG) finding in RBD involves the loss of the normal electromyographic atonia during REM sleep, also known as REM sleep without atonia (RSWA 
Case 4-2
A right-handed retired executive with 18 years of formal education began experiencing changes in cognition, mood and perception, motor functioning, and sleep in his mid seventies. He could not recall details of recent events and conversations, and he occasionally forgot to take his medications. He got lost while driving and later had trouble navigating in his own home. He developed a tremor, stooped posture, and shuffling gait. He was no longer able to care for himself. He verbalized despondence and poor appetite, which improved minimally after treatment with various selective serotonin reuptake inhibitors (SSRIs), but he denied hopelessness and suicidal ideation. He occasionally saw children or animals in the home that were not there, and he expressed concern that the children were stealing from him and might harm him. There was no history of dream enactment behavior, but he was falling asleep intermittently during the day. There were mild fluctuations in his symptomatology. His family arranged nursing home placement.
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Adapted with permission from Boeve BF. Diagnosis and management of the non-Alzheimer dementias. In: Noseworthy JW, ed. Neurological therapeutics: principles and practice. London: Martin Dunitz, 2003; 2826 -2854 avoided in patients with DLB (McKeith et al, 1996; McKeith et al, 2003) . There are infrequent reports of neuroleptic sensitivity even among the newer atypical neuroleptic agents, and some of these have been minimally effective for psychotic features (Walker et al, 1999) . Hallucinations, delusions, or agitation in patients with DLB as well as Parkinson's disease (with or without dementia) can improve with clozapine (Dewey and O'Suilleabhain, 2000) , risperidone (Leopold, 2000) , olanzapine (Aarsland et al, 1999; Cummings et al, 2002) , and quetiapine (Dewey and O'Suilleabhain, 2000; Tariot and Ismail, 2002) , as well as the cholinesterase inhibitors. Therefore, if problematic hallucinations, de-lusions, or agitation occur in patients with DLB who do not respond to the cholinesterase inhibitors, clinicians should consider quetiapine, clozapine, or olanzapine, keeping in mind that problematic orthostatism can occur with these agents. The mood-stabilizing effects of valproic acid or carbamazepine may be desired for some patients. Depression is very common in DLB, likely due in part to the serotonergic dysfunction in this disorder. The SSRIs are usually effective and well tolerated. Although none of the newer antidepressant agents has been shown to be superior to the others, the tricyclic antidepressants should be avoided in DLB because of their anticholinergic properties. Electroconvulsive therapy can be effective in some patients without significantly worsening cognition. Anxiety is also common and can be treated by an SSRI or buspirone.
Motor Dysfunction
Many of the parkinsonian signs and symptoms of DLB can respond to carbidopa/levodopa and the dopamine agonists. Their use is limited by the side effects, as these agents can exacerbate psychotic symptoms or orthostatism. Since many DLB patients have a postural rather than resting tremor, therapies effective for essential/familial tremor can be used if the tremor significantly impedes activities of daily living. Electroconvulsive therapy may also alleviate parkinsonism through unknown mechanisms. Most experts view dementia as an exclusionary factor when considering surgical forms of therapy such as pallidotomy and deepbrain stimulation for parkinsonism.
Autonomic Dysfunction
Orthostatic hypotension can occur in DLB, likely due to degenerative changes in the intermediolateral cell column of the spinal cord (Pakiam et al, 1999) . As in PD, management includes liberalizing salt in the diet, salt tablets, thigh-high compression stockings, fludrocortisone, and midodrine (Drugs to treat, 2002).
Sleep Disorders
Violent dreams/nightmares and potentially injurious dream enactment behavior are typical of RBD. However, patients with severe OSA can have features identical to RBD, and the nightmares and flailing limb behavior are eliminated with nasal CPAP. Hence, PSG +/À nasal CPAP trial should be considered in most DLB patients with a history suggesting RBD and/or OSA.
The goals of therapy for RBD are to minimize abnormal behavior and unpleasant dreams and, particularly, to minimize the potential for injury (Boeve et al, 2003a) . All patients and their bed partners should be counseled on simple steps to minimize injury, such as moving lamps and nightstands away from the bed and placing a mattress or cushion of some type on the floor adjacent to the bed (many patients use inexpensive foam padding (Olson et al, 2000; Schenck and Mahowald, 1990) . Although there is reluctance to use agents such as clonazepam in patients with dementia, exacerbation of cognitive impairment is rarely seen in DLB patients with RBD when 0.25 mg to 1.0 mg of clonazepam is used (Boeve et al, 2003a; Boeve et al, 2001a) . Recent experience with melatonin shows that doses ranging from 3 mg/night to 12 mg/night can be effective either as sole therapy, or in conjunction with clonazepam when either melatonin or clonazepam alone is ineffective (Boeve et al, 2003b) . Other drugs reported to improve RBD include donepezil, triazolam (Olson et al, 2000) , clozapine (Olson et al, 2000) , and quetiapine (Boeve et al, 2003a; Boeve et al, 2001a) .
Insomnia can be caused by degenerative changes in the key networks involved in the initiation and maintenance of sleep, by one or more primary sleep disorders (eg, restless legs syndrome, periodic limb movements in sleep, OSA, or central sleep apnea syndrome), by depression, and by medications (Boeve et al, 2001a) . A careful sleep history and PSG can help determine the cause(s) and possible therapies (Boeve et al, 2001a) . Contrary to popular belief, nasal CPAP therapy or bilevel positive airway pressure is tolerated by many patients with dementia, sometimes resulting in significant improvement in alertness and cognition (Boeve et al, 2001a) . If due to cholinesterase inhibitor therapy, dosing donepezil in the morning or dosing rivastigmine or galantamine no later than 6:00 PM may alleviate insomnia. Drugs effective for primary insomnia include trazodone, melatonin, chloral hydrate, zolpidem, and the atypical neuroleptics (eg, quetiapine, olanzapine, clozapine, or risperidone). Among the SSRIs, fluoxetine may precipitate or aggravate insomnia, while mirtazepine may improve insomnia.
There are no published data or anecdotal reports regarding gamma-hydroxybutyrate, which has profound sedating effects.
Excessive daytime somnolence can be caused by a similar set of etiologies noted above for insomnia (Boeve et al, 2001a) . Recent data in patients with PD and psychosis have shown narcoleptic-like features in some patients (Arnulf et al, 2000) . Modafinil can improve excessive daytime somnolence in PD patients, and there are anecdotal reports of modafinil or methylphenidate improving hypersomnia in patients with DLB (Boeve et al, 2001a) .
Although polysomnography can provide important diagnostic and therapeutic information, it can be arduous to perform in patients with DLB. Many sleep laboratories do not have simultaneous PSG video monitoring equipment, which is critical for evaluating patients with a parasomnia history. The slowing of the background EEG activity can make PSG scoring difficult. Non-neurologist sleep clinicians tend to focus on sleep-related breathing, although RBD and periodic limb movements in sleep are common in DLB. Therefore, DLB patients and their bed partners with sleep-related issues are often best served by referral to a sleep neurologist at an accredited sleep disorder center. Additional information on such neurologists and sleep disorder centers can be found by contacting the American Academy of Sleep Medicine (www.aasmnet.org). Figure 4 -3 (Petersen et al, 2001 ). Most of the published data involves patients with amnestic MCI, which often evolves into AD. The other MCI subtypes are theoretical constructs, and the qualitative and quantitative features of the nonamnestic MCI subtypes and the prodromal states for the non-AD dementias are still being defined. As new therapies are developed that may affect amyloid, tau, and synuclein pathophysiology in the various dementing conditions, identification of the underlying disorder in patients with early symptoms, including MCI, will become increasingly important.
CONTROVERSIES AND UNCERTAINTIES
Mild
Other Conditions Preceding Dementia With Lewy Bodies
Data gathered thus far suggests that RBD, parkinsonism, orthostatic hypotension, and MCI can each evolve into the full constellation of features characteristic of DLB (Case 4-3). It remains to be seen if other conditions, such as isolated visual hallucinations, anosmia, urinary incontinence, and other symptoms or disorders, can also represent the initial feature of evolving DLB (Figure 4-4) .
Genetics of Dementia With Lewy Bodies
There are several reports of familial DLB (Brett et al, 2002; Galvin et al, 2002; Tsuang et al, 2002) , and over half of the patients with probable DLB and RBD in one series had one or more first-degree relatives with parkinsonism or dementia (Boeve et al, 1998) . Several of the cases in this chapter have a positive family history of parkinsonism or dementia, as well. Even within those families with DLB, there is significant clinical and neuropathologic heterogeneity (Brett et al, 2002; Galvin et al, 2002; Gwinn-Hardy, 2002; Tsuang et al, 2002) . The DLB phenotype has been observed in at least one member of the Contursi kindred with a mutation in a-synuclein (Langston et al, 1998) . Undoubtedly numerous genetic factors that are associated with DLB and LBD have not yet been identified.
Alzheimer's Disease Coexisting With Lewy Body Disease
Pathologic studies have shown that as many as 80% of cases with limbic or neocortical LBD have some degree of coexisting Alzheimer pathology, leading some to classify LBD into ''pure'' (no Alzheimer pathology) and ''common'' (sparse to frequent Alzheimer pathology) forms (Kosaka, 2000) . Cases with common LBD tend to have diffuse +/À neuritic plaques but rather sparse to absent neurofibrillary tangles, particularly in the mesial temporal lobes, perhaps explaining why those 102 FIGURE 4-3 Subtypes and etiologic categories of mild cognitive impairment. 
Case 4-3
A right-handed semiretired business executive exhibited no significant cognitive or motor symptoms until he was hospitalized at age 66 for pneumonia. He experienced confusion, temporal and geographic disorientation, and mild paranoia. Laboratory testing and CT of the head were unrevealing. A neurologist diagnosed AD despite the absence of symptoms prior to the hospitalization. Upon the patient's discharge to home, he returned to his neurologic baseline. Over the subsequent 6 months, he mistakenly wrote addresses on the wrong side of several envelopes and experienced one episode of geographic disorientation while driving. He was greatly concerned about these symptoms, fearing he was truly developing AD.
Over the preceding 5 years, he also had exhibited typical features of RBD but had neither injured himself nor his wife. His past medical history was otherwise unremarkable. Family history was notable for dementia in his mother, with onset in her sixties.
Neurologic examination showed a score of 33/38 on the Short Test of Mental Status, with difficulties particularly in construction, and a mild postural tremor. Neuropsychological testing was only notable for impairment in visuospatial/visuoconstructional abilities. Laboratory studies for reversible causes of cognitive impairment were normal. MRI showed mild generalized cerebral cortical atrophy but no hippocampal atrophy. Based on these findings and his retained functional abilities, the patient was diagnosed with MCI (single nonmemory domain) and was initiated on high-dose vitamin E.
Evaluations over the subsequent 3 years showed the evolution of multiple cognitive, neuropsychiatric, motor, sleep, and autonomic changes. By age 67 he was experiencing difficulties in reasoning and decision making as well as prominent fatigue. Neuropsychological testing again showed visuospatial/visuoconstructive difficulties, with the only new finding being impairment on executive functioning. He underwent PSG, which confirmed RBD but only mild positional OSA and few periodic limb movements during sleep. By age 68 he had developed orthostatic hypotension and impotence, and many of the cardinal features of PD had evolved. Yet he continued to be functionally independent, with only mild difficulties in problem solving and decision making. Neuropsychological testing showed impairment on attention/concentration in addition to those aforementioned in other nonmemory domains. By age 69 he was experiencing daily visual hallucinations involving children and animals, delusions of intruders in the home, prominent apathy, and striking fluctuations in arousal, yet his cognitive symptoms had not progressed much. Neuropsychological testing continued to show marked impairment in visuospatial functioning and attention/ concentration, and while performance on delayed recall measures was dropping, his confrontation naming was almost perfect. By age 70 a suprapubic catheter had been placed to manage urinary incontinence, which improved his quality of life, but his functional abilities had declined greatly due to more prominent cognitive impairment and parkinsonism.
Comment. This patient presented with symptoms that caused him great concern but did not significantly affect activities of daily living. Clinical examination and neuropsychological testing showed impairment only in the visuospatial/visuoconstructive domain. Thus, his features at that time were consistent with nonamnestic MCI. Executive functions and attention/concentration were subsequently affected, and a dementia syndrome evolved, associated with the typical features of DLB. Some could argue that this case simply represents early cognitive deficiency associated with evolving PD, and dementia subsequently developed. In clinical practice such patients with worrisome symptoms but impairment in only one domain are often reassured that they do not have AD. The point here is that in some patients the concern is valid and indeed worrisome, as nonamnestic MCI can evolve into DLB.
with coexisting AD pathology still have relatively preserved memory functioning. Even those with autosomal dominant AD associated with mutations in presenilin 1, presenilin 2, or amyloid precursor protein, as well as patients with Down's syndrome, can have some degree of LBD pathology (Lippa et al, 1995; Trembath et al, 2003) . Some authorities view cases with AD and LBD pathology not as two distinct pathophysiologic processes but as related processes; this view has fostered the term Lewy body variant of Alzheimer's disease (Hansen and Samuel, 1997) , although it has been disputed (Dickson, 1990) . Clearly, more work is needed to clarify the clinical and pathophysiologic significance of Alzheimer pathology associated with Lewy body disease.
Dementia With Lewy Bodies and Parkinson's Disease With Dementia Controversy continues as to whether patients with typical features of PD who subsequently develop dementia (ie, PDD) have the same underlying pathophysiologic process as do patients with dementia, fluctuations, and visual hallucinations who subsequently develop parkinsonism (ie, DLB), differing primarily in the time course of when the various features became manifest (McKeith, 2000; Richard et al, 2002) . Recent evidence suggests that brain stem, limbic, +/À neocortical Lewy bodies and Lewy neurites characteristic of Lewy body disease are the common thread that ties PDD and DLB together (Apaydin et al, 2002; Dickson, 2002) . Neuropathologists are not able to predict which clinical phenotype was exhibited antemortem in those with LBD (Dickson, 2001; Dickson, 2002) . Furthermore, one can argue that the management of PDD is very similar, if not identical, to that of DLB. The available data therefore suggest that from the clinical, pathologic, and pathophysiologic perspectives, DLB and PDD are far more similar than different, but some authorities still contend that the two should be considered as separate entities (Richard et al, 2002 ). 
